# Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

> **NCT00288704** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 104 (actual)

## Conditions studied

- Familial Cold Autoinflammatory Syndrome (FCAS)
- Familial Cold Urticaria
- Muckle-Wells Syndrome (MWS)
- Genetic Diseases, Inborn

## Interventions

- **DRUG:** rilonacept 160 mg
- **DRUG:** Placebo
- **DRUG:** rilonacept 160 mg

## Key facts

- **NCT ID:** NCT00288704
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-06
- **Final completion:** 2008-08
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2011-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288704, "Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00288704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*